glp-1 muscle mass loss A Solution to Inhibitor's Troubling Side Effects Studies Show GLP-1 Weight-Loss Drugs

J Endocr Soc 4(9):bvaa097

Preprint at bioRxiv (2021)

aRWD: real-world data from cohort or registry studies (electronic health records, insurance-claims databases), bSRS: adverse drug reaction evidence from case reports and spontaneous-reporting systems, such as the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and World Health Organization (WHO) VigiBase

Its easy to get complacent once youre comfortable with injecting, but its still important to be diligent about rotating injection sites

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

Martin-Biggers et al